Displaying 1821 - 1840 of 4409
Statement from Federal Trade Commission’s Bureau of Competition Acting Director on District Court Ruling to Enjoin Advocate/NorthShore Hospital Merger
1703003 Informal Interpretation
FTC Approves Final Order Settling Charges that Puerto Rico Ophthalmologist Group Agreed to an Illegal Boycott of Health Plan
1703002 Informal Interpretation
1703001 Informal Interpretation
FTC Approves Final Order Preserving Competition in U.S. Markets for Animal Health Products
C.H. Boehringer Sohn, In the Matter of
Boehringer Ingelheim agreed to divest five types of animal health products in the United States in order to settle FTC charges that its proposed asset swap with Sanofi would likely be anticompetitive. Under the proposed swap, Boehringer Ingelheim acquired Sanofi’s animal care subsidiary, Merial, valued at $13.53 billion, and Sanofi obtained Boehringer Ingelheim’s consumer health care business unit, valued at $7.98 billion, as well as cash compensation of $5.54 billion. The FTC’s complaint alleges that without the divestitures the proposed asset swap would harm competition in the U.S. markets for various vaccines for companion animals (pets) and certain parasite control products for cattle and sheep. The proposed consent order preserves competition by requiring Boehringer Ingelheim to divest the companion animal vaccines to Eli Lilly and the company’s Elanco Animal Health division, and the parasite control products to Bayer AG.
FTC Approves Final Order Preserving Competition in U.S. Markets for Medical Devices Used in Cardiac and Vascular Catheterization
FTC Acting Chairman Ohlhausen Announces Tad Lipsky as Acting Director of Bureau of Competition; Other Staffing Changes
FTC Preserves Competition in Merger of Enbridge Inc. and Spectra Energy Corp
1702003 Informal Interpretation
FTC Requests Public Comment on Application from SuperValu Inc. to Sell Supermarket Divested by Safeway and Albertsons
1702002 Informal Interpretation
1702001 Informal Interpretation
FTC Approves Final Order with Parent Company of Bausch + Lomb
FTC Charges That Shire ViroPharma Inc. Abused Government Processes Through Serial, Sham Petitioning to Delay Generics and Maintain its Monopoly over Vancocin HCl Capsules
The Federal Trade Commission’s Path Ahead
Displaying 1821 - 1840 of 4409